Get the Stockscreener App
4.04
2.42%
-0.10
RAPT Therapeutics Inc stock is currently priced at $4.04, with a 24-hour trading volume of 541.16K.
It has seen a -2.42% decreased in the last 24 hours and a -49.75% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.16 pivot point. If it approaches the $3.97 support level, significant changes may occur.
Previous Close:
$4.14
Open:
$4.17
24h Volume:
541.16K
Market Cap:
$141.01M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-1.5019
EPS:
-2.69
Net Cash Flow:
$-98.17M
1W Performance:
-6.70%
1M Performance:
-49.75%
6M Performance:
-71.43%
1Y Performance:
-80.81%
1D Range:
$4.03
$4.2322
52W Range:
$3.98
$27.35
RAPT Therapeutics Inc Stock (RAPT) Company Profile
Name
RAPT Therapeutics Inc
Sector
Industry
Phone
650 489 9000
Address
561 Eccles Avenue, South San Francisco, CA
RAPT Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
RAPT Therapeutics Inc Stock (RAPT) Latest News
RAPT Therapeutics Inc [RAPT] Records 200-Day SMA of $15.72 – Knox Daily - Knox Daily
Knox Daily
Wolfe Research Reiterates Peer Perform Rating for RAPT Therapeutics (NASDAQ:RAPT) - Defense World
Defense World
RAPT: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
The InvestChronicle
Rapt Therapeutics stock downgraded to Peerperform by Wolfe Research - Investing.com South Africa
Investing.com South Africa
Wolfe downgrades RAPT, but still sees "immense" upside potential (NASDAQ:RAPT) - Seeking Alpha
Seeking Alpha
RAPT Therapeutics (NASDAQ:RAPT) Receives "Peer Perform" Rating from Wolfe Research - MarketBeat
MarketBeat
RAPT Therapeutics Inc Stock (RAPT) Financials Data
RAPT Therapeutics Inc (RAPT) Revenue 2024
RAPT reported a revenue (TTM) of $3.25 million for the quarter ending June 30, 2022, a -33.98% decline year-over-year.
RAPT Therapeutics Inc (RAPT) Net Income 2024
RAPT net income (TTM) was -$116.80 million for the quarter ending December 31, 2023, a -39.31% decrease year-over-year.
RAPT Therapeutics Inc (RAPT) Cash Flow 2024
RAPT recorded a free cash flow (TTM) of -$98.17 million for the quarter ending December 31, 2023, a -37.08% decrease year-over-year.
RAPT Therapeutics Inc (RAPT) Earnings per Share 2024
RAPT earnings per share (TTM) was -$3.05 for the quarter ending December 31, 2023, a -18.22% decline year-over-year.
RAPT Therapeutics Inc Stock (RAPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brockstedt Dirk G. | Chief Scientific Officer |
Dec 29 '23 |
Option Exercise |
6.18 |
8,000 |
49,440 |
27,070 |
| HO WILLIAM | Chief Medical Officer |
Dec 21 '23 |
Sale |
21.68 |
2,500 |
54,200 |
15,020 |
| HO WILLIAM | Chief Medical Officer |
Nov 28 '23 |
Sale |
13.72 |
1,500 |
20,580 |
17,520 |
| HO WILLIAM | Chief Medical Officer |
Oct 03 '23 |
Sale |
15.77 |
2,500 |
39,425 |
18,789 |
| HO WILLIAM | Chief Medical Officer |
Aug 18 '23 |
Sale |
18.92 |
2,500 |
47,300 |
21,289 |
| HO WILLIAM | Chief Medical Officer |
Jul 28 '23 |
Option Exercise |
12.00 |
460 |
5,520 |
23,789 |
| HO WILLIAM | Chief Medical Officer |
Jun 23 '23 |
Option Exercise |
12.00 |
920 |
11,040 |
23,329 |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
0.77%
1.20%
Cap:
|
Volume (24h):